

***Approaches to assessment  
of substances for which  
no safe threshold  
can be set***

**Josef Schlatter  
Swiss Federal Office of Public Health  
Food Toxicology Section  
Zürich Switzerland**

**Chair of the EFSA CONTAM Panel**

# Main Question in Food Toxicology

---



**What is a „safe” human exposure dose over lifetime ??**

**e.g. a dose with ”no appreciable or a negligible risk”**

**↔ acute exposure**

# Extrapolation from animals to Man:

- Most sensitive species
- Lowest NOAEL [or BMD(L)]
- Apply uncertainty factors (UF)



ADI: intentionally added compounds

TDI, PTWI: Contaminants


## Problematic areas:

---

- Allergies and intolerances
- Non-monotonic dose-response curves (D-R)
- Assumption of a non-thresholded D-R

**NOTE:**  
**the existence of a threshold cannot be proven or disproven experimentally**

# Hazard Characterization: Non-monotonic D-R



# Irreversible toxic effects

- **CNS Central nervous system damage (almost no regeneration)**
- **Cataracts**
- **Malformations (cell death during organogenesis)**
- **Carcinogenicity**  
(DNA damage, disturbed cell-cell communication)
- **Genotoxicity (DNA damage)**

**Most toxicological effects are thresholded**

**e.g. there is a dose without “appreciable” risk**

# Issues with genotoxic compounds

---

- **Absence of a threshold in their mode of action is assumed, i.e. there is no dose without a potential effect**
- **No generally agreed paradigm for the risk assessment**

**Most difficult issue in food safety is to advise on potential risks to human health for unavoidable compounds found in food, which are both genotoxic and carcinogenic**

- **As low as reasonably achievable (ALARA)**
- **Dose-response extrapolation outside the observed dose range**

# Limitation of ALARA approach


---

- Advice does **not** take into account available scientific information on **potency** of the compound and extent of human **exposure**
- Continuous improvement of analytical methods leads to lower **detection limits** and increases the number of genotoxic carcinogens detected in food
- **ALARA does not provide risk managers with a scientific basis for setting priorities or for taking actions**




# Hazard Characterization: Non-thresholded D-R

Effect





# Extrapolation from observable range to low-dose exposure

Number of cases of cancer per lifetime



# Ethyl Carbamate



Modelling by Dr. Felix Wächter, Ciba Geigy Basel (1986)

# Extrapolation from observable range to low-dose exposure

---

EFSA Scientific Committee has **serious reservations** about extrapolating from animal tumour data at high doses using **mathematical modelling** to estimate risks to humans at low exposures for compounds that are both genotoxic and carcinogenic

**„Model used more important than actual data“**

- sign. non-linearities in toxicokinetics and mode of actions
- cytotoxicity at high doses may influence the D-R

# Extrapolation from observable range to low-dose exposure


---

- Homeostatic and cytoprotective mechanisms
- Abundance of cellular targets

⇒ **minimum degree of interaction of the substance with the critical sites must be reached to elicit a toxicologically relevant effect**

- **Scientific Committee is of the opinion that there is a ‘practical’ threshold for genotoxic compounds**
- **Levels below which cancer incidence is not increased cannot be identified on scientific grounds**
- **Margin of exposure approach (MOE) was considered appropriate for genotoxic compounds**

# Hazard Characterization: Non-thresholded D-R



# Chemicals in food and feed




**Natural constituents**

**additives**

**pesticides**

**Food processing**

**animal drugs**



**packaging materials**

**biotechnology**




**environmental contaminants**

**nutrients**

**overfeeding, deficiencies**

**Dietary fibers**





Thank you for your attention !!



**This paper was produced for a meeting organized by Health & Consumer Protection DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumer Protection DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.**